US Blood Cancer Drug Market & Pipeline Analysis 2015

July 2015 | 1100 pages | ID: UFE551ACC3AEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Pharmaceutical companies have identified the opportunities to generate significant revenues from blood cancer segment in US. Escalating blood cancer incidences, high unmet medical necessities and demand for better therapeutics are some major factors behind growth of US blood cancer market segment. Higher investments have been made by pharmaceutical companies in order to come forth with better therapeutics for generating significant revenues. As a result, numerous therapeutic have been introduced in US market for the successful treatment of blood cancer. Several innovative therapeutics are at different stages of clinical trials which would be introduced in coming years.

Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs.

Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market.

Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase.

'US Blood Cancer Drug Market & Pipeline Analysis 2015' Report Highlights:

• Blood Cancer Incidence & Prevalence
• Blood Cancer Drug Market Overview
• Blood Cancer Drug Market Dynamics
• Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight
• Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs
• Majority Drugs in Phase-I Clinical Trials: 128 Drugs
• Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis
• Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs

Contents

1. US BLOOD CANCER INCIDENCE & PREVALENCE

1.1 Leukemia: Cancer of White Blood Cells (WBC)
  1.1.1 Acute Lymphocytic Leukemia (ALL)
  1.1.2 Acute Myeloid Leukemia (AML)
  1.1.3 Chronic Lymphocytic Leukemia (CLL)
  1.1.4 Chronic Myeloid Leukemia (CML)
1.2 Lymphoma: Cancer of Lymphatic System
  1.2.1 Hodgkin Lymphoma
  1.2.2 Non-Hodgkin Lymphoma (NHL)
1.3 Myeloma

2. US BLOOD CANCER DRUG MARKET OVERVIEW

2.1 Current Market Scenario
2.2 US Blood Cancer Drug Clinical Pipeline Overview

3. US BLOOD CANCER DRUG MARKET DYNAMICS

3.1 Favorable Market Parameters
3.2 Commercialization Challenges

4. US BLOOD CANCER DRUG MARKET FUTURE PROSPECTS

5. MECHANISM OF BLOOD CANCER THERAPEUTICS

6. LEUKEMIA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

6.1 Research till Registered
6.2 Discontinued & Suspended Leukemia Drug Clinical Insight

7. MARKETED LEUKEMIA DRUG CLINICAL INSIGHT

7.1 Alemtuzumab (Campath)
7.2 Arsenic Trioxide (Trisenox)
7.3 Bosutinib (Bosulif)
7.4 Clofarabine
7.5 Crisantaspase (Erwinaze)
7.6 Dasatinib (Sprycel)
7.7 Fludarabine (Fludara)
7.8 Idarubicin (Idamycin)
7.9 Imatinib (Gleevec)
7.10 Irinotecan
7.11 Mercaptopurine Oral Suspension (Purixan™)
7.12 Mitoxantrone (Novantrone)
7.13 Nilotinib (Tasigna)
7.14 Obinutuzumab (Gazyva)
7.15 Ofatumumab (Arzerra)
7.16 Omacetaxine Mepesuccinate (Synribo)
7.17 Pegaspargase (Oncaspar)
7.18 Pentostatin (Nipent)
7.19 Ponatinib (Iclusig)
7.20 Sargramostim (Leukine)
7.21 Tretinoin
7.22 Vincristine Liposomal - Spectrum Pharmaceuticals (Marqibo)

8. LYMPHOMA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

8.1 Research till Registered
8.2 Discontinued & Suspended Lymphoma Drug Clinical Insight

9. MARKETED LYMPHOMA DRUG CLINICAL INSIGHT

9.1 Belinostat (Beleodaq)
9.2 Bexarotene Oral (Targretin)
9.3 Bexarotene Topical (Targretin)
9.4 Brentuximab Vedotin (Adcetris)
9.5 Chlormethine (Valchlor™)
9.6 Denileukin Diftitox (ONTAK)
9.7 Ibritumomab Tiuxetan (Zevalin)
9.8 Interferon Alpha-2b (Intron A)
9.9 Pralatrexate (Folotyn)
9.10 Romidepsin (Istodax)
9.11 Vorinostat (Zolinza)

10. MULTIPLE MYELOMA DRUG CLINICAL PIPELINE BY COMPANY & PHASE

10.1 Research till Preregistration
10.2 Discontinued & No Development Reported in Multiple Myeloma Drug Clinical Insight

11. MARKETED MULTIPLE MYELOMA DRUG CLINICAL INSIGHT

11.1 Carfilzomib (Kyprolis)
11.2 Doxorubicin Liposomal – ALZA
11.3 Pomalidomide (Pomalyst)
11.4 Thalidomide (Thalomid)
11.5 Zoledronic Acid (Zometa)

12. MULTIPLE BLOOD CANCER DRUG CLINICAL PIPELINE BY COMPANY & PHASE

12.1 Research till Preregistration
12.2 Discontinued & Suspended Multiple Blood Cancer Drug Clinical Insight

13. MARKETED MULTIPLE BLOOD CANCER DRUG CLINICAL INSIGHT

13.1 Azacitidine (Vidaza)
13.2 Bendamustine (Treanda)
13.3 Bortezomib (Velcade)
13.4 Cladribine (Leustatin)
13.5 Decitabine (Dacogen)
13.6 Ibrutinib (Imbruvica)
13.7 Idelalisib
13.8 Lenalidomide (Revlimid)
13.9 Nelarabine (Arranon)
13.10 Rituximab (Rituxan)

14. COMPETITIVE LANDSCAPE

14.1 Actelion Pharmaceuticals
14.2 Amgen
14.3 ARIAD Pharmaceuticals
14.4 Astellas Pharma
14.5 Baxter BioScience
14.6 Bayer HealthCare Pharmaceuticals Inc.
14.7 Biogen Idec
14.8 Bristol-Myers Squibb
14.9 CASI Pharmaceuticals
14.10 Celera Genomics Group
14.11 Celgene Corporation
14.12 Eisai Co Ltd
14.13 Genmab
14.14 Gilead Sciences
14.15 GlaxoSmithKline
14.16 Hospira
14.17 Johnson & Johnson
14.18 Millennium Pharmaceuticals
14.19 Nova Laboratories
14.20 Novartis
14.21 Onxeo SA
14.22 Onyx Pharmaceuticals
14.23 Otsuka Pharmaceutical
14.24 Pfizer
14.25 Roche
14.26 Scripps Clinic
14.27 Seattle Genetics
14.28 SRI International
14.29 Southern Research Institute
14.30 Tekmira Pharmaceuticals Corporation
14.31 Teva Pharmaceutical Industries
14.32 Yakult Honsha

List Of Figures

LIST OF FIGURES

Figure 1-1: Main Types of Blood Cancer
Figure 1-2: Percentage of Leukemia in New Cancer Cases, 2015
Figure 1-3: Percentage of Leukemia in all Cancer Related Deaths, 2015
Figure 1-4: Leukemia Estimated Cases, 2013-2015
Figure 1-5: Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-6: Leukemia Estimated New Cases in Females, 2013-2015
Figure 1-7: Leukemia Estimated Deaths, 2013-2015
Figure 1-8: Leukemia Estimated Deaths in Males, 2013-3015
Figure 1-9: Leukemia Estimated Deaths in Females, 2013-2015
Figure 1-10: Percentage of Acute Lymphocytic Leukemia in Cancer Related Deaths, 2015
Figure 1-11: Percentage of Acute Lymphocytic Leukemia in New Cancer Cases, 2015
Figure 1-12: Acute Lymphocytic Leukemia Estimated New Cases, 2013-2015
Figure 1-13: Acute Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-14: Acute Lymphocytic Leukemia Estimated New Cases in Female, 2013-2015
Figure 1-15: Acute Lymphocytic Leukemia Estimated Deaths, 2013-2015
Figure 1-16: Acute Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015
Figure 1-17: Acute Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015
Figure 1-18: Acute Myeloid Leukemia Estimated New Cases, 2013-2015
Figure 1-19: Acute Myeloid Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-20: Acute Myeloid Leukemia Estimated New Cases in Females, 2013-2015
Figure 1-21: Percentage of Acute Myeloid Leukemia in New Cancer Cases, 2015
Figure 1-22: Percentage of Acute Myeloid Leukemia in all Cancer Deaths, 2015
Figure 1-23: Acute Myeloid Leukemia Estimated Deaths, 2013-2015
Figure 1-24: Acute Myeloid Leukemia Estimated Deaths in Male, 2013-2015
Figure 1-25: Acute Myeloid Leukemia Estimated Deaths in Female, 2013-2015
Figure 1-26: Chronic Lymphocytic Leukemia Estimated New Cases, 2013-2015
Figure 1-27: Chronic Lymphocytic Leukemia Estimated New Cases in Males, 2013-2015
Figure 1-28: Chronic Lymphocytic Leukemia Estimated New Cases in Females, 2013-2015
Figure 1-29: Chronic Lymphocytic Leukemia Estimated Deaths, 2013-2015
Figure 1-30: Percentage of Chronic Lymphocytic Leukemia in New Cancer Cases, 2015
Figure 1-31: Percentage of Chronic Lymphocytic Leukemia in all Cancer Related Deaths, 2015
Figure 1-32: Chronic Lymphocytic Leukemia Estimated Deaths in Males, 2013-2015
Figure 1-33: Chronic Lymphocytic Leukemia Estimated Deaths in Females, 2013-2015
Figure 1-34: Percentage of Chronic Myeloid Leukemia in New Cancer Cases, 2015
Figure 1-35: Percentage of Chronic Myeloid Leukemia in all Cancer Related Deaths, 2015
Figure 1-36: Categories of Chronic Myeloid Leukemia (CML)
Figure 1-37: Chronic Myeloid Leukemia Estimated New Cases, 2013-2015
Figure 1-38: Estimated New Cases of Chronic Myeloid Leukemia in Males, 2013-2015
Figure 1-39: Estimated New Cases of Chronic Myeloid Leukemia in Females, 2013-2015
Figure 1-40: Estimated Deaths due to Chronic Myeloid Leukemia, 2013-2015
Figure 1-41: Estimated Deaths due to Chronic Myeloid Leukemia in Male, 2013-2015
Figure 1-42: Estimated Deaths due to Chronic Myeloid Leukemia in Female, 2013-2015
Figure 1-43: Types of Lymphoma
Figure 1-44: Identification of Different Types of Lymphomas
Figure 1-45: Lymphoma Estimated New Cases, 2013-2015
Figure 1-46: Estimated New Cases of Lymphoma in Males, 2013-2015
Figure 1-47: Estimated New Cases of Lymphoma in Females, 2013-2015
Figure 1-48: Estimated Lymphoma Deaths, 2013-2015
Figure 1-49: Lymphoma Estimated Deaths in Males, 2013-2015
Figure 1-50: Lymphoma Estimated Deaths in Females, 2013-2015
Figure 1-51: Percentage of Hodgkin Lymphoma in New Cancer Cases, 2015
Figure 1-52: Percentage of Hodgkin Lymphoma in all Cancer Related Deaths, 2015
Figure 1-53: Estimated New Cases of Hodgkin Lymphoma, 2013-2015
Figure 1-54: Estimated New Cases of Hodgkin Lymphoma in Male, 2013-2015
Figure 1-55: Estimated New Cases of Hodgkin Lymphoma in Females, 2013-2015
Figure 1-56: Hodgkin Lymphoma Estimated Deaths, 2013-2015
Figure 1-57: Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
Figure 1-58: Hodgkin Lymphoma Estimated Deaths in Female, 2013-2015
Figure 1-59: Percentage of Non-Hodgkin Lymphoma (NHL) in New Cancer Cases, 2015
Figure 1-60: Percentage of Non-Hodgkin Lymphoma in all Cancer Related Deaths, 2015
Figure 1-61: Non-Hodgkin Lymphoma Estimated New Cases, 2013-2015
Figure 1-62: Non-Hodgkin Lymphoma Estimated New Cases in Male, 2013-2015
Figure 1-63: Non-Hodgkin Lymphoma Estimated New Cases in Female, 2013-2015
Figure 1-64: Non-Hodgkin Lymphoma Estimated Deaths, 2013-2015
Figure 1-65: Non-Hodgkin Lymphoma Estimated Deaths in Males, 2013-2015
Figure 1-66: Non-Hodgkin Lymphoma Estimated Deaths in Females, 2015- 2013
Figure 1-67: Percentage of Myeloma in New Cancer Cases, 2015
Figure 1-68: Myeloma Estimated New Cases, 2013-2015
Figure 1-69: Myeloma Estimated New Cases in Males, 2013-2105
Figure 1-70: Myeloma Estimated New Cases in Females, 2013-2015
Figure 1-71: Percentage of Myeloma in all Cancer Related Deaths, 2015
Figure 1-72: Myeloma Estimated Deaths, 2013-2015
Figure 1-73: Myeloma Estimated Deaths in Males, 2013-2015
Figure 1-74: Myeloma Estimated Deaths in Females, 2013-2015
Figure 2-1: Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-2: Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-3: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-4: No Development Reported Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-5: Discontinued Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-6: Discontinued Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-7: Suspended Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-8: Suspended Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-9: Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-10: Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-11: No Development Reported Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-12: No Development Reported Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-13: Discontinued Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-14: Discontinued Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-15: Suspended Leukemia Drug Pipeline Overview by Phase (%), 2015
Figure 2-16: Suspended Leukemia Drug Pipeline Overview by Phase (Number), 2015
Figure 2-17: Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-18: Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-19: No Development Reported Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-20: No Development Reported Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-21: Discontinued Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-22: Discontinued Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-23: Suspended Lymphoma Drug Pipeline Overview by Phase (%), 2015
Figure 2-24: Suspended Lymphoma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-25: Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
Figure 2-26: Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-27: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
Figure 2-28: No Development Reported Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-29: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (%), 2015
Figure 2-30: Discontinued Multiple Myeloma Drug Pipeline Overview by Phase (Number), 2015
Figure 2-31: Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-32: Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-33: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-34: No Development Reported Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-35: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-36: Discontinued Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 2-37: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (%), 2015
Figure 2-38: Suspended Multiple Blood Cancer Drug Pipeline Overview by Phase (Number), 2015
Figure 3-1: US Blood Cancer Drug Market Favorable Parameters
Figure 3-2: US Blood Cancer Drug Market Commercialization Challenges
Figure 5-1: Mechanism of Idelalisib
Figure 5-2: Mechanism of Imatinib
Figure 5-3: Mechanism of Rituximab
Figure 5-4: Mechanism of Doxorubicin
Figure 5-5: Mechanism of Carfilzomib
Figure 14-1: Actelion Pharmaceuticals Clinical Pipeline
Figure 14-2: Amgen Clinical Pipeline
Figure 14-3: ARIAD Clinical Pipeline
Figure 14-4: Casi Pharmaceutical Clinical Pipeline
Figure 14-5: Celgene Clinical Pipeline
Figure 14-6: Gilead Sciences Clinical Pipeline
Figure 14-7: GalaxoSmithKline Clinical Pipeline
Figure 14-8: Millennium Pharmaceuticals Clinical Pipeline
Figure 14-9: Novartis Clinical Pipeline
Figure 14-10: Onxeo SA Clinical Pipeline
Figure 14-11: Roche Clinical Pipeline
Figure 14-12: Tekmira Clinical Pipeline

COMPANIES

Actelion Pharmaceuticals,
Amgen,
ARIAD Pharmaceuticals,
Astellas Pharma,
Baxter BioScience,
Bayer HealthCare Pharmaceuticals Inc.,
Biogen Idec,
Bristol-Myers Squibb,
CASI Pharmaceuticals,
Celera Genomics Group,
Celgene Corporation,
Eisai Co Ltd,
Genmab,
Gilead Sciences,
GlaxoSmithKline,
Hospira,
Johnson & Johnson,
Millennium Pharmaceuticals,
Nova Laboratories,
Novartis,
Onxeo SA,
Onyx Pharmaceuticals,
Otsuka Pharmaceutical,
Pfizer,
Roche,
Scripps Clinic,
Seattle Genetics,
SRI International,
Southern Research Institute,
Tekmira Pharmaceuticals Corporation,
Teva Pharmaceutical Industries,
Yakult Honsha